| Name | CU-115 |
| Description | CU-115 is a selective and potent TLR8 antagonist with IC50 of 1.04 µM and =>50 µM for TLR8 and TLR7, respectively. CU-115 decreases production of TNF-α and IL-1β activated by R-848 in THP-1 cells. |
| In vitro | CU-115 (1, 5, and 20 µM) inhibits TLR9 to 10-25% inhibition. CU-115 (5-20 µM) inhibits increases in the activity of type I IFN transcriptional induced by the ssRNA nucleic acid ligands 3p-hpRNA or G3-YSD. CU-115 (5-20 µM) abolishes the TNF-α production activated by R848 (1 µg/ml) and represses the expression of IL-1β in hTHP-1 cells. CU-115 does not modulate the NF-kB inhibition induced by Pam2CSK4, Pam3CSK4, LPS, R848, Poly(I:C), and Flic in HEK-293 TLR1/2, TLR2/6, TLR3, and TLR4 cells[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn Oil : 2 mg/mL (3.51 mM), Sonication is recommended. DMSO : 45 mg/mL (79.06 mM), Sonication is recommended.
|
| Keywords | TLR8 | CU-115 | CU115 | CU 115 |
| Inhibitors Related | D-Glucuronic acid | Hydroxychloroquine | Benzyl alcohol | (±)-Naringenin | Chloroquine phosphate | Chloranil | Thiamine hydrochloride | 2,4,5-Trimethoxybenzoic acid | Resiquimod | Stevioside | DHBP | Atazanavir sulfate |
| Related Compound Libraries | Bioactive Compound Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Antioxidant Compound Library | Inhibitor Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |